Tarsus Pharmaceuticals Reports on Shareholder Vote Matters

TL;DR

Tarsus Pharma held a shareholder vote on June 13th. Details filed today.

AI Summary

Tarsus Pharmaceuticals, Inc. filed an 8-K on June 18, 2024, reporting on matters submitted to a vote of security holders on June 13, 2024. The filing details the company's principal executive offices located at 15440 Laguna Canyon Road, Suite 160, Irvine, CA 92618, and its telephone number is (949) 418-1801.

Why It Matters

This filing indicates that Tarsus Pharmaceuticals held a shareholder vote, which is a key governance event for public companies and can signal important decisions or approvals.

Risk Assessment

Risk Level: low — The filing is a routine 8-K reporting a shareholder vote, with no immediate financial or operational risks disclosed.

Key Players & Entities

• Tarsus Pharmaceuticals, Inc. (company) — Registrant
• June 13, 2024 (date) — Date of earliest event reported
• June 18, 2024 (date) — Date of report
• 15440 Laguna Canyon Road, Suite 160, Irvine, CA 92618 (location) — Principal executive offices
• (949) 418-1801 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share TARS The Nasdaq Sto

Filing Documents

• tars-20240613.htm (8-K) — 32KB
• 0001819790-24-000087.txt ( ) — 157KB
• tars-20240613.xsd (EX-101.SCH) — 2KB
• tars-20240613_lab.xml (EX-101.LAB) — 22KB
• tars-20240613_pre.xml (EX-101.PRE) — 13KB
• tars-20240613_htm.xml (XML) — 3KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 13, 2024, Tarsus Pharmaceuticals, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting"). The Company filed its definitive proxy statement for the proposals voted upon at the Annual Meeting with the Securities and Exchange Commission on April 26, 2024 (the "Proxy Statement"). At the close of business on April 15, 2024, the record date of the Annual Meeting, the Company had 37,776,665 shares of common stock outstanding and entitled to vote. The holders of a total of 31,978,938 shares of common stock were present at the Annual Meeting, either in person or by proxy, which total constituted a quorum of the issued and outstanding shares on the record date of the Annual Meeting. The following proposals were submitted to the Company's stockholders at the Annual Meeting: 1. The election of two nominees as Class I directors to serve until the Company's 2027 annual meeting of stockholders. 2. The ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. The number of votes cast for and against or withheld and the number of abstentions and broker non-votes with respect to each matter voted upon, as applicable, are set forth below: 1. Board of Directors Election Results The following nominees were elected to serve as Class I directors for a term that will continue until the 2027 annual meeting of stockholders or until their respective successors have been duly elected and qualified. The number of votes cast for and withheld and the number broker non-votes for each nominee were as follows: Director Name Votes For Votes Withheld Broker Non-Votes Bhaskar Chaudhuri, Ph.D. 21,766,101 2,941,857 7,270,980 William J. Link, Ph.D. 20,817,032 3,890,926 7,270,980 The following directors, in addition to Dr. Chaudhuri and Dr. Link, will continue to serve as members of ou

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TARSUS PHARMACEUTICALS, INC. Date: June 18, 2024 /s/ Bryan Wahl Bryan Wahl General Counsel and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR